Nutriband Inc. (NTRB)

Market Cap	65.00M
Revenue (ttm)	2.02M
Net Income (ttm)	-6.37M
Shares Out	11.04M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	370.37
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,568
Open	6.05
Previous Close	5.99
Day's Range	5.67 - 6.05
52-Week Range	1.53 - 6.75
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	May 31, 2024

About NTRB

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA buprenorphine and AVERSA methylphenidate, and other transdermal pharmaceutical products. The company was incorporated in 2016 and is headquartered in Orlando, Florida.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Gareth Sheridan
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRB

Financial Performance

In 2023, Nutriband's revenue was $2.09 million, an increase of 0.27% compared to the previous year's $2.08 million. Losses were -$5.49 million, 22.3% more than in 2022.